Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
November 08 2022 - 8:30AM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), today announced that it will report financial results for
the third quarter ended September 30, 2022 on Monday, November 14,
2022, before the open of U.S. markets. Following the announcement,
the Company will host a conference call and webcast at 8:30 a.m. ET
to provide a corporate update and review the financial results.
Register for the live webcast using the link
here or by visiting the “Investors” section of the Alaunos website
at www.alaunos.com. To participate via telephone, please register
in advance at this link. Upon registration, all telephone
participants will receive a confirmation email detailing how to
join the conference call, including the dial-in number along with a
unique passcode and registrant ID that can be used to access the
call. After the live webcast, the event will be archived on the
Company’s website for approximately 30 days after the call.
About Alaunos
TherapeuticsAlaunos is a clinical-stage oncology-focused
cell therapy company, focused on developing T-cell receptor (TCR)
therapies based on its proprietary, non-viral Sleeping Beauty gene
transfer technology and its TCR library targeting shared
tumor-specific hotspot mutations in key oncogenic genes including
KRAS, TP53 and EGFR. The Company has a clinical and strategic
collaboration with the National Cancer Institute. For more
information, please visit www.alaunos.com.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Sep 2023 to Sep 2024